Novo Nordisk has teamed up on a project that rewards diabetes patients with lower copays if they stick with their meds.
Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.
After one false alarm, Rigel Pharmaceuticals has officially won FDA approval for its lead rare disease therapy, Tavalisse.
Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.
Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.
Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.
Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.
A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.
Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."